The FDA has delayed its review deadline for GSK’s multiple myeloma drug Blenrep to October 23 to further evaluate additional data submitted by the company. This follows a negative advisory committee vote over ocular toxicity concerns and questions on dose optimization. The delay extends the regulatory uncertainty for Blenrep, which the FDA had previously approved for late-line multiple myeloma but was withdrawn from markets after a failed confirmatory trial. GSK remains engaged with the FDA to seek approval for combination regimens in patients with prior therapies.